Tarsa Therapeutics Announces Addition of Senior Level Clinical and Regulatory Expertise
PHILADELPHIA, Feb. 18 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced the addition of two executives to its senior management team. David Krause, M.D., F.A.C.P., has joined as Chief Medical Officer and Thomas C. Wicks, Ph.D., has joined as Vice President Global Regulatory Affairs. Tarsa's unique, once-daily oral form of calcitonin is in a global Phase III trial for the treatment of post-menopausal osteoporosis.
David Brand, President and CEO of Tarsa noted, "We are fortunate to have recruited two highly experienced and capable individuals to oversee the global clinical development and regulatory strategy for our oral calcitonin product. David Krause brings Tarsa extensive experience in global clinical development and medical affairs, including recent experience in the osteoporosis field. Tom Wicks has wide-ranging experience in global regulatory management, including playing a key role in the regulatory strategy for the blockbuster drug Plavix® and helping to register a calcitonin product in Japan. We look forward to their important contributions to advancing our ongoing Phase III program."
Dr. Krause has over 20 years of pharmaceutical industry experience. Prior to Tarsa, he served as Chief Medical Officer and Senior Vice President and Head of R&D at Zelos Therapeutics, which develops osteoporosis therapies. Earlier, Dr. Krause was Executive Vice President and Chief Medical Officer of Vicuron Pharmaceuticals. Previously, Dr. Krause held positions of increasing responsibility at GlaxoSmithKline and its predecessor companies, leading worldwide clinical development groups and serving as Vice President of Medical Strategy and Cross-Therapeutic Affairs. He holds an M.D. from Temple University School of Medicine and a B.A. degree from Pennsylvania State University, where he was recently named a Centennial Fellow. Dr. Krause has authored over 70 scientific publications and abstracts and is a Fellow of the American College of Physicians.
Dr. Wicks has over 25 years' experience in regulatory strategic planning and execution. Prior to joining Tarsa, Dr. Wicks was Vice President of Regulatory Affairs and Quality Assurance at Mt Cook Pharma. Previously, he served as Vice President of Regulatory Affairs at Odyssey Pharmaceuticals. Prior to Odyssey, Dr. Wicks was Senior Director, Global Regulatory Affairs at Purdue Pharma. Previously, Dr. Wicks served in positions of increasing responsibility at several Sanofi-Aventis predecessor companies, including Vice President of Regulatory Affairs at Sanofi, where he played a key role in the regulatory strategy that led to approval of Plavix and directed early clinical efforts for the bisphosphonate Skelid®. At the Rorer/Armour companies, he led a team responsible for the registration of salmon calcitonin in Japan. Dr. Wicks holds a Ph.D. from Georgetown University and a B.S. degree from the University of Maine. He completed an NIH post-doctoral fellowship at Georgetown University Medical Center.
Separately, Tarsa announced that the company has moved into its permanent offices at 8 Penn Center, 1628 JFK Boulevard, suite 1400 in Philadelphia, PA.
About Tarsa Therapeutics
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that inhibits bone resorption, the process underlying osteoporosis. Availability of an oral formulation is expected to generate wider use of this established osteoporosis treatment, which currently is available only in injectable and intranasal formulations. Tarsa's oral calcitonin has generated promising data in Phase II studies and a global Phase III clinical program is now underway. Tarsa is based in Philadelphia, PA.
GendeLLindheim BioCom Partners
Source: Tarsa Therapeutics, Inc.
CONTACT: For Tarsa: Barbara Lindheim, GendeLLindheim BioCom Partners,